Growing attempts to develop biomarkers to guide therapy within triple-negative breast cancer may lead to more effective regimens or to novel therapeutic targets.
Daniel G. Stover, MD
Advertisement
Articles by Daniel G. Stover, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Full Approval to Afami-Cel for Advanced Synovial Sarcoma
2
Venetoclax/Ibrutinib Clears Resistance Mutations in BTK Inhibitor–Resistant CLL
3
Dose-Modified, Fixed-Duration Ibrutinib Plus Venetoclax Meets ORR End Point in Untreated CLL
4
Sigvotatug Vedotin Fails to Improve OS in Advanced, Pretreated Nonsquamous NSCLC
5